Australia markets close in 1 hour 57 minutes

Prestige BioPharma Limited (950210.KS)

KSE - KSE Delayed price. Currency in KRW
Add to watchlist
8,070.00+60.00 (+0.75%)
As of 12:54PM KST. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
30/06/2023
30/06/2022
30/06/2021
30/06/2020
Total revenue
-
161,841
-
-
-
Gross profit
-
161,841
-
-
-
Operating expenses
Selling general and administrative
46,477,972
39,597,228
42,846,063
9,312,225
6,204,649
Total operating expenses
77,998,256
-905,396
58,516,240
18,384,004
10,873,116
Operating income or loss
-77,649,466
1,067,237
-58,516,240
-18,384,004
-10,873,116
Interest expense
-
950,797
18,851
6,198
-
Income before tax
-65,483,770
-2,095,487
-210,649,475
-7,356,859
-14,898,393
Income tax expense
643,347
763,278
800,662
34,077
98,473
Income from continuing operations
-66,127,117
-2,858,766
-211,450,137
-7,390,936
-14,996,866
Net income
-46,029,137
17,569,286
-211,450,137
-7,390,936
-14,996,866
Net income available to common shareholders
-46,029,137
17,569,286
-211,450,137
-7,390,936
-14,996,866
Basic EPS
-541.80
293.60
-3.52k
-143.20
-351.60
Diluted EPS
-541.80
293.60
-3.52k
-143.20
-351.60
Basic average shares
60,096
59,841
60,085
51,613
42,653
Diluted average shares
60,096
59,841
60,085
51,613
42,653